Calcium inhibitor inhibits high glucose-induced hypertrophy of H9C2 cells

XIAOHONG XU1,2*, LUOYANG RUAN3*, XIAOHUA TIAN2, FENGJUAN PAN2, CAILAN YANG2 and GUOSHENG LIU4
1Department of Pediatrics, Guangzhou Hospital of Integrated Traditional and West Medicine, Guangzhou, Guangdong 510800; 2Department of Pediatrics, Central Hospital of Guangdong Nongken, Zhanjiang, Guangdong 524002; 3Department of Anesthesiology, Guangzhou Hospital of Integrated Traditional and West Medicine, Guangzhou, Guangdong 510800; 4Department of Pediatrics, The First Clinical Medical College of Jinan University, Guangzhou, Guangdong 510632, P.R. China

Received May 7, 2019; Accepted May 21, 2020

DOI: 10.3892/mmr.2020.11275

Abstract. The aim of the present study was to explore whether the hypertrophy of H9C2 cardiomyocytes was induced by high glucose, to investigate whether the calcium channel inhibitor (Norvasc) could inhibit this process and to clarify the possible signaling pathways. The morphology of H9C2 cells was observed under an optical microscope, and the cell surface area was measured by Image Pro Plus 6.1 software. Furthermore, fluorescence spectrophotometry was used to detect intracellular calcium concentration ([Ca^{2+}]_i). ELISA was performed to detect calcineurin (CaN) activity; reverse transcription-quantitative PCR and western blotting were performed to detect the mRNA and protein expression levels of CaNβ subunit (CaNβ), nuclear factor of activated T cells 3 (NFAT3) and β type myosin heavy chain (β-MHC). Cell size was increased with the increase in glucose concentration of culture medium at 48 and 72 h, respectively, and decreased with the addition of Norvasc compared with those without Norvasc (P<0.05). There was no significant difference in cell size with the addition of Norvasc compared with cells cultured with 5 mM glucose (P>0.05). The average [Ca^{2+}]_i activity of single cells in the 48- and 72-h culture groups treated with 50 mM glucose was significantly higher than cells treated with 5 mM glucose (P<0.05); and the fluorescent value of average [Ca^{2+}]_i activity of single cells was lower, following the addition of Norvasc than that without Norvasc (P<0.05). CaN activity in the 48- and 72-h culture group treated with 50 mM glucose was markedly higher than that treated with 5 mM glucose, and the activity of CaN notably decreased with the addition of Norvasc compared with those without Norvasc. The mRNA and protein expression levels of CaNβ, NFAT3 and β-MHC in the 48- and 72-h culture groups treated with 50 mM glucose were all significantly higher than those treated with 5 mM glucose (P<0.05). The mRNA and protein expression of CaNβ, NFAT3 and β-MHC cultured with 50 mM glucose were significantly decreased following the addition of Norvasc (P<0.05). Thus, the calcium channel inhibitor Norvasc may inhibit high glucose-induced hypertrophy of H9C2 cardiomyocytes by inhibiting the Ca^{2+}-CaN-NFAT3 signaling pathway.

Introduction

China has a high incidence of diabetes mellitus, with the number of diabetic patients exceeding 90 million (1). At present, ~300 million individuals have been diagnosed with diabetes mellitus worldwide (2). Large-scale clinical studies have reported that patients with diabetes have a significantly higher risk of heart injury and cardiac insufficiency compared with those without diabetes (3-7). Diabetic cardiomyopathy is defined as a heart injury, which is independent of other diseases and is caused by diabetes mellitus itself (8), and manifests as left ventricular diastolic dysfunction at the early stage of onset and systolic dysfunction at the later stage. If not treated properly, diabetic cardiomyopathy can develop into heart failure, arrhythmia, cardiogenic shock and even sudden death in severe cases (9).

There are multiple clinical strategies to prevent and treat diabetic cardiomyopathy. However, the effect of reducing the incidence and mortality of cardiovascular complications requires improvement in patients with diabetes. Therefore, the study of diabetic cardiomyopathy requires extensive investigation. It is currently hypothesized that several mechanisms are involved in the pathogenesis of diabetic cardiomyopathy, including changes in myocardial energy metabolism and calcium signaling (10-13).

As an important secondary messenger, calcium plays an important role in the excitation-contraction coupling of the heart and regulates the expression of cardiac-related genes.

Correspondence to: Professor Guosheng Liu, Department of Pediatrics, The First Clinical Medical College of Jinan University, 601 Huangpu Avenue West, Guangzhou, Guangdong 510632, P.R. China
E-mail: tlgs@jnu.edu.cn

*Contributed equally

Key words: diabetic cardiomyopathy, myocardial hypertrophy, amlodipine besylate, calcineurin, nuclear factor of activated T cells 3
The role of Ca\(^{2+}\) signaling and its dependent signal transduction pathway in cardiac hypertrophy and myocardial apoptosis has been widely recognized by researchers. Ca\(^{2+}\) is ubiquitous in cells and plays an important role not only in the electrical activity of the heart but also as a direct activator of myofilament contraction. Calcium enters the cardiomyocytes through voltage-gated calcium channels which selectively permeate calcium ions into the cell when there is a change from a high voltage to a low voltage inside of the cell. Voltage-gated calcium ion channels are subdivided into six fundamental types according to their electrophysiology and sensitivity to certain drugs and toxins. These voltage-gated calcium ion channels are named L-, T-, N-, P-, Q- and R-channels; L-channels have a long activation and high conductance, and are mainly located in skeletal, cardiac and vascular muscle and are involved in its contraction; T-channels have a transient opening and are involved in calcium ion entry when the membrane is depolarized; N-channels are involved in neurotransmitter release; P/Q-channels are mainly localized in the nerve terminals of cells of the cerebellum and are involved in neurotransmitter release; and R-channels are mainly localized in cell bodies and are involved in Ca\(^{2+}\)-dependent action potentials (14).

In the myocardium, the L-type calcium channel is the main pathway for calcium to enter the cell (15).

The role of the Ca\(^{2+}\)-calcineurin (CaN)-nuclear factor of activated T cells 3 (nFaT3) signaling pathway in cardiac development has gained interest in recent years, and several classes of antihypertensive drugs, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and calcium channel blockers (CCBs), have been demonstrated to reverse hypertrophy in humans (16,17). CCBs were introduced for the treatment of hypertension in the 1980s. Their use was subsequently expanded to disorders such as angina pectoris, paroxysmal supraventricular tachycardia, hypertrophic cardiomyopathy, coronary spasm and cerebral vasospasm (18). Evidence from experimental studies indicate that CCBs nifedipine, nisoldipine and amlodipine additionally lead to regression of interstitial and perivascular myocardial fibrosis, which may contribute to the improvement of diastolic function and coronary reserve (19).

Norvasc is the brand name of amlodipine besylate. Amlodipine does not increase cardiovascular morbidity or mortality in patients with severe heart failure (20) and multiple studies have reported that amlodipine can reduce cardiac remodeling in spontaneously hypertensive rats and myocardial infarction in rats (21-23). Therefore, Norvasc was selected for the current study to determine whether it could inhibit hypertrophy of H9C2 cardiomyocytes induced by high glucose.

The aim of the present study was to investigate high glucose-induced hypertrophy of H9C2 cells and its possible pathogenesis, from the perspective of the calcium signaling pathway, to provide a theoretical basis for the identification of potential targets for clinical prevention and treatment of this disease.

**Materials and methods**

**Materials.** Cell culture reagents: FBS (cat. no. SH30087.01; Hyclone; GE Healthcare Life Sciences); DMEM-high glucose culture medium (50 mM; cat. no. 11965-092; Gibco; Thermo Fisher Scientific, Inc.); DMEM-low glucose culture medium (5 mM; cat. no. 10567-014; Gibco; Thermo Fisher Scientific, Inc.). H9C2 cells were rat embryonic cardiomyocytes purchased from the Cell Resource Center of Shanghai Academy of Life Sciences, Chinese Academy of Sciences; Norvasc was obtained from Sigma-Aldrich (Merck KGaA); ELISA assay kit of CaN (cat. no. E-EL-R0134c) was purchased from Elabscience Biotechnology Co., Ltd.; Fluo-3 AM (calcium ion fluorescent probe; cat. no. S1056) was from Beyotime Institute of Biotechnology; DNase I (RNase-free) was purchased from Beijing Transgen Biotech Co., Ltd.; reverse transcription kit and real-time PCR kit were obtained from Vazyme; CnAβ, nuclear factor of activated T cells 3 (NFAT3), β type myosin heavy chain (β-MHC) and b-actin primary antibodies (cat. nos. ab3673, ab66781, ab207926 and ab8227, respectively) were all purchased from Abcam.

**Cell culture.** Following thawing, cells (1×10\(^4\)-1×10\(^5\)/ml) were cultured in DMEM containing 10% FBS in a 5% CO\(_2\) incubator with saturated humidity at 37°C.

**Experimental grouping.** The experimental groups were as follows: i) A1, 48-h culture group treated with 5 mM glucose; ii) B1, 48-h culture group treated with 50 mM glucose; iii) C1, 48-h culture group treated with 50 mM glucose + 25 nmol/l Norvasc; iv) A2, 72-h culture group treated with 5 mM glucose; v) B2, 72-h culture group treated with 50 mM glucose; vi) C2, 72-h culture group treated with 50 mM glucose + 25 nmol/l Norvasc. All cell treatments used DMEM containing 10% FBS.

**Determination of cell surface area.** Cell morphology were observed using an optical microscope, and the cell surface area was measured by Image-Pro Plus 6.1 software (Media Cybernetics, Inc.). A total of 3 fields of view were observed at magnification x20.

**Determination of intracellular calcium ([Ca\(^{2+}\)]\(_i\)) activity.** Cell culture media was removed and cells (1×10\(^4\)-1×10\(^7\)/ml) were washed with PBS. Fluo-3 (2 µM), diluted in serum-free media was added for 1.5 h at 37°C, 5% CO\(_2\). Fluo-3 was removed, followed by two PBS washes and the addition of cell culture media. Fluorescence microscopy (magnification, x20) was performed to detect [Ca\(^{2+}\)]\(_i\).

**Determination of cellular CaN enzyme activity.** Enzyme activity of CaN was measured using a rat CaN ELISA assay kit, according to the manufacturer's instructions.

**Detection of CaN, NFAT3 and β-MHC mRNA expression in myocardial cells by reverse transcription-quantitative (RT-q) PCR.** The extraction of RNA was achieved using TRIzol® (Invitrogen; Thermo Fisher Scientific, Inc.). Next, the reaction mixture was prepared with RNase-free DNase I, followed by digestion for 30 min at 37°C and inactivation for 10 min at 65°C to remove DNA. Reverse transcription was conducted with the addition of template RNA and primer mixtures at 42°C for 1 h, then resting on ice for 2 min. This was followed by the addition of cDNA (10X) to the primer reaction mixture. The RNA concentration was measured with NanoDrop™ 1000.
(Thermo Fisher Scientific, Inc.). The cycling conditions for qPCR were as follows: 95°C for 30 sec, 40 cycles at 95°C for 10 sec followed by 60°C for 34 sec. The melting curve was drawn within the temperature range of 60-95°C. The primer sequences were: Rat-GAPDH forward (F), 5'-CATCAACGA CCTCTCATTG-3' and reverse (R), 5'-GAAGATGGGTAT GGTTTCC-3'; rat-CaN F, 5'-ATGTTGCCAGTGAGTG TT-3' and R, 5'-GAGAGATCCCTCGATGTGTT-3'; NFAT3 F, 5'-CCACAAGGCATTGGAGACAT-3' and R, 5'-TCACCA GCAGCAGCAGCAG-3'; and rat-β-MHC F, 5'-AATGAAACAC CCGAGCAAAGG-3'; and R, 5'-CGGTCAGCTGAGAGATA AGAC-3'. mRNA levels were quantified by relative quantification and analyzed using the 2-ΔΔCq method (24).

Detection of CaN, NFAT3 and β-MHC protein expression in myocardial cells by western blotting. Culture plates of H9c2 cells (1x10^4-1x10^5/ml) were washed with pre-cooled PBS and treated with pre-cooled lysis buffer (CWBio) on ice for 30 min. The lysis products were centrifuged for 20 min at 8,300 x g at 4°C to collect the supernatant. Furthermore, 2 µl supernatant was used to determine the protein concentration by using a BCA protein quantitative kit. Protein samples (50 µg/well) were separated by SDS-PAGE on a 10% gel. Electrophoresis was performed for 20 min at a constant voltage of 100 V, and for 40 min at a constant voltage of 140 V. Subsequently, the proteins were transferred to a PVDF membrane, followed by three TBS washes. Following the removal of TBS, the membranes were blocked using TBS with Tween-20 buffer (20 mM Tris-HCl, 150 mM NaCl and 0.1% Tween-20) containing 5% non-fat milk for 2 h at room temperature. The membrane was then incubated with TBST buffer (20 mM Tris-HCl, 150 mM NaCl and 0.1% Tween-20) containing 5% non-fat milk with the following primary antibodies, polyclonal rabbit anti-human CaN (1:1,000), polyclonal rabbit anti-human NFAT3 (1:1,000), polyclonal rabbit anti-human β-MHC (1:1,000) and polyclonal rabbit anti-human β-actin, overnight at 4°C. Following three washes with 1X PBS, the PVDF membrane was incubated with a horseradish peroxidase-conjugated anti-rabbit secondary antibodies (1:10,000; cat. no. 111-035-003; Jackson ImmunoResearch Laboratories, Inc.) at room temperature for 2 h. The PVDF membrane was washed five times with PBS (15 min each), and developed using an ECL kit (Beijing ComWin Biotech Co., Ltd.).

Statistical analysis. GraphPad Prism 7 (GraphPad Software, Inc.) was used for statistical analysis. Data were analyzed with two-way ANOVA adjusted for multiple comparisons. Multiple comparisons between the groups was performed using Bonferroni tests. The bilateral inspection level for α was 0.05, and P<0.05 was considered to indicate a statistically significant difference.

Results

Cell swelling analysis. The cell size in B1 and B2 groups was increased compared with cells in A1 and A2 groups after 48 and 72 h of culture under different conditions. Cell size was decreased following the addition of Norvasc compared with those without the addition of Norvasc under the same conditions. There was no significant difference between the C1 and C2 and A1 and A2 groups, respectively. Furthermore, there was no significant difference in cell size between the A1 and A2 groups, B1 and B2 groups, and C1 and C2 groups, respectively. The statistical analysis chart is presented in Fig. 1.

Determination of [Ca^{2+}]_i activity in each group. Following 48 and 72 h of culture, the fluorescent values of [Ca^{2+}]_i activity in B1, B2, C1 and C2 groups were increased compared with the A1 and A2 groups, respectively. Following the addition of Norvasc, the fluorescent value of [Ca^{2+}]_i activity in each group was notably lower than that without Norvasc under the same conditions. In addition, no obvious difference was found in the fluorescent values of intracellular [Ca^{2+}]_i activity.
between the A1 and A2 groups, B1 and B2 groups, and C1 and C2 groups, respectively. Images of fluorescent staining are presented in Fig. 2. The statistical analysis chart is presented in Fig. 3.

**Cellular CaN enzyme activity.** The CaN concentration was increased in the B1 and B2 groups compared with the A1 and A2 groups, following 48 and 72 h of culture, respectively. With the addition of Norvasc, the concentration of CaN in each group was significantly lower than that without Norvasc. The concentration standard curve is presented in Fig. 4A and the statistical analysis chart is presented in Fig. 4B.

**CaN, NFAT3 and β-MHC mRNA expression levels of H9C2 cells determined by RT-qPCR.**

**Changes in CaN mRNA expression in H9C2 cells.** The mRNA expression of CaN in B1 and B2 groups was increased compared with that in the A1 and A2 groups, following 48 and 72 h of culture, respectively. Furthermore, the mRNA expression level of CaN was lower with the addition of Norvasc than that without Norvasc. The mRNA expression of CaN in the C1 and C2 groups had no significant difference between the A1 and A2 groups respectively. The statistical analysis chart is presented in Fig. 5.

**Changes in NFAT3 mRNA expression in H9C2 cells.** Following 48 and 72 h of culture, the mRNA expression of NFAT3 in the B1 and B2 groups was increased compared with the A1 and A2 groups, and expression in the C1 group was increased compared with the A1 group. The addition of Norvasc resulted in decreased NFAT3 mRNA expression than that without Norvasc. Additionally, no significant difference was observed in the mRNA expression level of NFAT3 in the C2 groups compared with that in the A2 groups. The statistical analysis chart is presented in Fig. 6.

**Changes in β-MHC mRNA expression in H9C2 cells.** A trend towards increased β-MHC mRNA expression was observed in B1 and B2 groups compared with the A1 and A2 groups following 48 and 72 h of culture, under different culture conditions. Following the addition of Norvasc, the mRNA expression of β-MHC was lower than that without Norvasc under the same conditions. The mRNA expression level of β-MHC in groups C1 and C2 were without any significant difference between groups A1 and A2, respectively. Furthermore, there was no statistical difference between the A1 and A2 groups or C1 and C2 groups. With the prolongation of culture time, a trend towards decreased β-MHC mRNA expression was observed in the B2 group compared with the B1 group. The statistical analysis chart is shown in Fig. 7.
Detection of CaN, NFAT3 and β-MHC protein expression in H9C2 cells by western blotting. Representative western blotting images are presented in Fig. 8.

Detection of CaN protein expression in H9C2 cells by western blotting. The protein expression of CaN in B1 and B2 groups was increased compared with the A1 and A2 groups, respectively, following 48 and 72 h of culture under different culture conditions. Protein expression of CaN was significantly decreased in groups C1 and C2 compared with the B1 and B2 groups, respectively, following the addition of Norvasc. There was no significant difference between the C1 and C2 groups and A1 and A2 groups, respectively. The statistical analysis chart is presented in Fig. 9.

Detection of NFAT3 protein expression in H9C2 cells by western blotting. The protein expression of NFAT3 was increased in the B1 and B2 groups compared with that of the A1 and A2 groups, respectively, following 48 and 72 h of culture under different culture conditions. However, the protein expression of NFAT3 was decreased with the addition of Norvasc compared to that without Norvasc, under the same conditions. The NFAT3 protein expression was also increased in the C1 and C2 groups compared with that in the A1 and A2 groups. The statistical analysis chart is presented in Fig. 10.

Detection of β-MHC protein expression in H9C2 cells by western blotting. The trend of increased protein expression of β-MHC was observed in the B1 and B2 groups compared with that of the A1 and A2 groups, respectively, following 48 and 72 h of culture under different culture conditions. The addition of Norvasc resulted in decreased β-MHC protein expression compared with that without the addition of Norvasc, under the same conditions. Additionally, the expression of β-MHC protein in the C1 and C2 groups was not significantly different with that in the A1 and A2 groups. There was no significant difference in the protein expression of β-MHC in group A and B and C with the prolongation of culture time. The statistical analysis chart is presented in Fig. 11.

Discussion

The World Health Organization predicts that 300 million individuals worldwide will be diagnosed with diabetes mellitus...
Patients with diabetes are prone to cardiovascular diseases, and the probability of myocardial infarction is 10 times higher than that of non-diabetic patients (26,27). First proposed by Rubler et al (28) in 1972, diabetic cardiomyopathy is a type of heart disease that is independent of coronary heart disease, valve disease and hypertensive heart disease, and is mainly characterized by diastolic dysfunction in the early stage and systolic dysfunction at the late stage. The pathogenesis is complex, with the main pathological changes including myocardial inflammation, metabolic disorders, myocardial cell apoptosis and fibrosis (29,30). The duration of hyperglycemia serves as an important indicator in determining the severity of heart failure caused by diabetic cardiomyopathy (31). Therefore, hyperglycemia is studied as an independent risk factor of myocardial injury caused by diabetic cardiomyopathy (32,33).

High glucose will stimulate cardiac hypertrophy in a variety of ways (34-37). In the present study, it was found that high glucose could lead to an increase in the average individual volume of H9C2 cells (Fig. 6). Research investigating the aberrant molecular processes that occur during cardiac hypertrophy has used primary cardiomyocytes from neonatal rat hearts as the standard experimental in vitro system. In addition, some studies have made use of the H9c2 rat cardiomyoblast cell line (38,39), as it was found by Watkins et al (40) that the H9C2 cell line and primary neonatal cardiomyocyte cells exhibit similar hypertrophic responses in vitro. Therefore, the H9C2 cell line was selected for the present study, which also has
the advantage of being an animal-free alternative. However, this is also a limitation of the present study because primary neonatal cardiomyocyte cells were not used. The role of the Ca²⁺-CaN-NFAT3 signaling pathway in cardiac development has become a research area of interest in recent years. The activation of Ca²⁺-dependent CaN α subunit (CaNα) has been frequently observed in human heart hypertrophy and heart failure (41,42). In mice, increased intracellular calcium is known to activate CaNα, which can bind and dephosphorylate the NFAT transcription factor family of activated T-nuclear factors. Subsequently, NFAT is transferred from the cytoplasm to the nucleus, activating the specific expression of various genes associated with cardiac hypertrophy, such as atrial natriuretic factor, brain natriuretic peptide (BNP), and β-MHC in the heart. This leads to increased nucleic acid synthesis of myocardial cell protein and increased cardiac cell volume, and finally cardiac hypertrophy (43,44). Transgenic mice overexpressing a consistently active form of CaN-specific cardiomyocytes, MHC-CnA, have been found to suffer from cardiac hypertrophy at 18 days following birth, with varying degrees of progression to heart failure and sudden death (45).

Several different studies have found that the Ca²⁺-CaN-NFAT3 signaling pathway plays a role in cardiac hypertrophy. Daskoulidou et al (46) found that increased Orai 1 expression could mediate an increase in the calcium current of the store-operated calcium entry channel, in order to regulate calcium in cardiac cells, which may be induced by hyperglycemia through the activation of the CaN/NFATc3 signaling pathway. Somvanshi et al (47) revealed that the activation of the somatostatin receptor 2 (SSTR2) not only inhibited the expression and activity of CaN phosphatase, but also hindered the dephosphorylation of NFAT and nuclear translocation, which provided evidence that SSTR2 could protect the heart by regulating the Ca²⁺-associated signaling pathway, leading to cardiac hypertrophy. The T-type calcium channel, Cav3.2 could be induced by Egr1 (early growth response 1), which is released at the early stage of myocardial hypertrophy due to the early pressure overload, to regulate cardiac hypertrophy through the CaN phosphatase-NFAT signaling pathway (48). A previous study also revealed that the activity of the CaN signaling pathway may be activated by the bacteria Porphyromonas gingivalis, and further lead to cardiomyocyte hypertrophy and cell death of cultured H9c2 cardiomyocytes (49). The Ca²⁺-CaN-NFAT3 pathway is considered to be the crucial mechanism in mediating the development of cardiac hypertrophy and therefore, the role of the Ca²⁺-CaN-NFAT3 signaling pathway in hyperglycemia-induced myocardial hypertrophy was investigated in the present study. Following the determination of [Ca²⁺]i and mRNA and protein expression levels of CaN, NFAT and β-MHC, it was revealed that high glucose could induce an increase in [Ca²⁺]i and CaN concentration. Furthermore, high glucose increased the mRNA and protein levels of CaN, NFAT and β-MHC, and in combination with the cell morphology data, suggest the involvement of the Ca²⁺-CaN-NFAT signaling pathway in hyperglycemia-induced H9c2 cells.
The activation of CaN mainly depends on the increase in intracellular Ca\(^{2+}\), and its activity is regulated by the change in intracellular Ca\(^{2+}\) concentration (50). The continuous maintenance of NFAT in the nucleus requires a continuous and oscillating increase in calcium (51) in order to maintain the activated form of CaN phosphatase. This CaN-dependent signal is sensitive to the inhibition of calcium channel blockers, such as verapamil, or CaN inhibitors, such as cyclosporine A (CSA) and tacrolimus (FK-506) (52-54). L-type Ca\(^{2+}\) channels are widely distributed in the heart, smooth and skeletal muscles (55,56). In the heart and smooth muscle cells, the L-type Ca\(^{2+}\) channels are responsible for the inward movement of Ca\(^{2+}\), thereby causing contraction. In skeletal muscles, these channels act as voltage sensors in excitation-contraction coupling. L-type calcium channels consist of several subunits, namely, α1, α2, β, γ and δ (14). The α1 subunit consists of four homologous structural domains, and contains transmembrane pores, through which calcium ions can be obtained, as well as calcium antagonist binding sites adjacent to the pores, which are connected to each other and to the calcium channel via allosteric junctions (57,58).

The L-type calcium channel is considered to be the main source of calcium that can activate CaN-NFAT3 signal transduction (59). Thus, L-type calcium channel inhibitors have become a research area of interest and an important therapeutic target for cardiac hypertrophy. Cardiac remodeling, which involves structural and functional changes at the molecular, cellular, tissue and whole-organ levels, can be used to determine the clinical course of heart failure (60). A number of studies have reported that amlodipine can reduce cardiac remodeling in spontaneously hypertensive rats and myocardial infarction in rats (61,62). Valsartan monotherapy as well as amlodipine combined with atorvastatin remodeling, which involves structural and functional changes at the molecular, cellular, tissue and whole-organ levels, can be used to determine the clinical course of heart failure (60). A number of studies have reported that amlodipine can reduce cardiac remodeling in spontaneously hypertensive rats and myocardial infarction in rats (61,62). Valsartan monotherapy as well as amlodipine combined with atorvastatin had a greater beneficial effect on the myocardial hypertrophy. These benefits may be associated with the cumulative effect of the drug on inhibiting NADPH oxidase-mediated reactive oxygen species (63). Amlodipine has also been found to improve cardiomyocyte hypertrophy by inhibiting the phosphorylation of the epithelial growth factor receptor (64). Losartan, amlodipine, and particularly fosinopril can inhibit myocardial cell apoptosis, prevent myocardial fibrosis, and reverse cardiac hypertrophy; the inhibition of the cardiac renin-angiotensin-aldosterone system may be the mechanism of the cardioprotective effects of these three drugs (65). Meo et al (66) reported a decrease in L-type calcium current in cardiomyocytes in a glycosuria mouse model, induced by streptozotocin. In addition to the traditional L-type calcium channel, it is generally considered that Orai 1-mediated calcium store-operated calcium channel also participates in the calcium regulation of cardiomyocytes. In a diabetic model, Orai 1 expression was increased in both cardiomyocytes and smooth muscle cells (46,67). Amlodipine sulfonate is an L-type calcium channel blocker, which can selectively inhibit the transmembrane domain to inhibit calcium ions from entering cardiomyocytes. Several studies have demonstrated that amlodipine sulfonate could inhibit CaN-NFAT3 and thus inhibit cardiac hypertrophy (68,69). Therefore, the L-type calcium channel amlodipine bensulfonate, Norvasc, was selected to investigate whether intracellular influx of Ca\(^{2+}\) was observed in H9C2 cells cultured with high glucose, in order to induce changes in intracellular calcium concentration and the activation of CaN, thereby activating the signaling pathway, and ultimately causing cardiomyocyte hypertrophy.

The main purpose of the present study was to investigate whether Norvasc could induce the recovery of cardiomyocyte hypertrophy and inhibit Ca\(^{2+}\)-CaN-NFAT3 signaling. Following the addition of Norvasc, the activity of [Ca\(^{2+}\)i], CaN concentration, CaN mRNA and protein expression in the corresponding groups were all significantly decreased, which indicated that Norvasc reduced CaN expression. Thus, intracellular calcium could activate CaN and promote its expression. The present study demonstrated that calcium channel inhibitors could alleviate cell hypertrophy and are more effective in inhibiting cell hypertrophy following prolonged action. Bugyei-Twum et al (70) also found that high glucose in vitro induced the activation of Smad in H9C2 cells and promoted cardiac fibrosis and hypertrophy through transcriptional coregulator p300, and Chen et al (71) revealed that lercanidipine may ameliorate cardiomyocyte hypertrophy, partially by blocking Ca-NFAT3 and CaMKII-HDAC4 signaling. These findings are consistent with the present study.

The signal transduction mechanism of myocardial hypertrophy is complex. In addition to Ca\(^{2+}\)-CaN-NFAT3 signaling pathway, there may be other signaling pathways, which may have interactions with CaN-NFAT3. Thus, further studies are required, including the use of specific inhibitors, such as CSA, to identify other pathways. Liu et al (72) demonstrated that lipopolysaccharide (LPS) treatment leads to myocardial hypertrophy via the calcineurin/NFAT-3 signaling pathway in H9C2 cells. They further provided a link between the LPS-induced inflammatory response and the calcineurin/NFAT-3 signaling pathway that mediates the development of cardiac hypertrophy. LPS treatment was found to significantly promote the activation and nuclear translocation of NFAT3 and mediated the development of cardiac hypertrophy as a transcription factor. The cell size, actin fiber, atrial natriuretic peptide and BNP levels were assessed following the use of ERK1/2 inhibitors, p38 MAPK inhibitors, JNK 1/2 inhibitors, CaN inhibitors and NF-KB inhibitors, which demonstrated that only the CaN inhibitor could significantly inhibit NFAT3 nuclear localization. The present study provides findings that can be used to determine subsequent future studies.

In summary, the present experimental design and results suggest that, the calcium channel inhibitor Norvasc may inhibit hyperglycemia in H9C2 cells, which may result from the activation of the Ca\(^{2+}\)-CaN-NFAT3 signaling pathway by high glucose levels.

Acknowledgements

The authors would like to thank Dr Shasha Han (Department of Pediatrics, The First Clinical Medical College of Jinan University, Guangzhou, China) for her technical support.

Funding

The present study was supported by NSFC (grant nos. 81741083, 81801492).
Availability of data and materials

The datasets used and/or analyzed are available from the corresponding author on reasonable request.

Authors' contributions

XX, LR, XT, FP and GL made substantial contributions to conception and design of the study. XX, LR, XT, FP and CY provided resources, contributed to research and validation of the results, interpreted data and wrote the original draft preparation. XX, LR, FP and GL reviewed and edited the manuscript. XX, LR and GL supervised the study. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH and Hu FB: Diabetes in Asia: Epidemiology, risk factors, and pathophysiology. JAMA 301: 2129-2140, 2009.
2. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U and Shaw JE: Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 103: 137-149, 2014.
3. Lamblin N, Fertin M, De Groote P and Bauters C: Cardiac remodeling and heart failure after a first anterior myocardial infarction in patients with diabetes mellitus. J Cardiovasc Med (Hagerstown) 13: 353-359, 2012.
4. Tochiya M, Makino H, Tamanaha T, Matsuo M, Hishida A, Koetzka R, Ohata Y, Tomita T, Son C, Miyamoto Y, et al: Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study. J Diabetes Investig 11: 400-404, 2020.
5. Sardu C, Barbieri M, Santamaria M, Giordano V, Sacra C, Paolillo P, Spirito A, Marfella R, Paolillo G and Rizzo MR: Multipolar pacing by cardiac resynchronization therapy with a defibrillators treatment in type 2 diabetes mellitus failing heart patients: Impact on responders rate, and clinical outcomes. Cardiovasc Diabetol 16: 75, 2017.
6. Kannel WB and McGee DL: Diabetes and cardiovascular disease: The Framingham study. JAMA 241: 2035-2038, 1979.
7. Lind M, Bounias I, Olsson M, Gudbjörnsdottr S, Svensson AM and Rosengren A: Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: An observational study. Lancet 378: 140-149, 2011.
8. Bayeva M, Sawicki KT and Ardehali H: Taking diabetes to heart-deregulation of myocardial lipid metabolism in diabetic cardiomyopathy. J Am Heart Assoc 2: e433, 2013.
9. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, et al: Prevalence and control of diabetes in Chinese adults. JAMA 310: 948-959, 2013.
10. Kim HW, Ch YS, Lee HR, Park SY and Kim YH: Diabetic alterations in cardiac sarcoplasmic reticulum Ca$^{2+}$-ATPase and phospholamban protein expression. Life Sci 70: 367-379, 2001.
11. Cai L, Li W, Wang G, Guo L, Jiang Y and Kang YJ: Hyperglycemia-induced apoptosis in mouse myocardium: Mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 51: 1938-1948, 2002.
12. Way KJ, Isshiki K, Suzuma K, Yokota T, Zvagelsky D, Schoen FJ, Sandusky GE, Pechous PA, Vlahos CJ, Waksassak H and King GL: Expression of connective tissue growth factor is increased in injured myocardium associated with protein kinase C beta2 activation and diabetes. Diabetes 51: 2709-2718, 2002.
13. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME and Burrell LM: A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92: 785-792, 2003.
14. Catterall WA: Structure and regulation of voltage-gated Ca$^{2+}$ channels. Annu Rev Cell Dev Biol 16: 521-555, 2000.
15. Dolphin AC: Voltage-gated calcium channels: Their discovery, function and importance as drug targets. Brain Neurosci Adv 2: 239821288794805, 2018.
16. Klingbeil AU, Schneider M, Martus P, Messerli FH and Schmieder RE: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 115: 41-46, 2003.
17. Fagard RH, Celis H, Thijs L and Wouters S: Regression of left ventricular mass by antihypertensive treatment: A meta-analysis of randomized comparative studies. Hypertension 54: 1084-1091, 2009.
18. Pecas L, Gilau L, Coltau M, Pasca R, Domuta G, Baican M and Hecht A: Calcium channel blockers reduce blood pressure in part by inhibiting vascular smooth muscle carbonic anhydrase I. Cardiovascular Drug Ther 14: 523-528, 2000.
19. Bangalore S, Fakheri R, Toklu B and Messerli FH: Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: Systematic review and meta-analysis of randomized trials. BMJ 352: i438, 2016.
20. Packer M, O’Connor CM, Ghali JK, Pressler ML, Carlson PE, Belkin RM, Miller AB, Neuberger GW, Frit D, Wertheimer JH, et al: Effect of amiodarone on morbidity and mortality in severe chronic heart failure. Prospective randomized amiodarone survival evaluation study group. N Engl J Med 335: 1107-1114, 1996.
21. Lu J, Hao J, Du H, Xiao B, Li Y, Yang X and Cui W: Amiodarone and atorvastatin improve hypertensive cardiac remodeling through regulation of MMPs/TIMPs in SHR Rats. Cell Physiol Biochem 39: 47-60, 2016.
22. Nagasawa K, Takahashi K, Matsuura N, Takatsu M, Hattori T, Watanabe S, Harada E, Niinuma K, Murohara T and Nagata K: Comparative effects of valsartan in combination with cilnidipine or amiodarone on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. Hypertens Res 38: 39-47, 2015.
23. Whelan P, Zhang HP and Kloner RA: Biphasic response to amiodarone after myocardial infarction in rats: Association with cardiac vascular remodeling. Cardiovasc Pathol 2: 85-93, 2000.
24. Livak KJ and Schmidtge TD: Analysis of relative gene expression levels using real-time quantitative PCR and the 2(-Delta Delta CT) method. Methods 25: 402-408, 2001.
25. Verkrachtsy A and Fernyhough P: Mitochondrial malfunction and Ca$^{2+}$ dyshomeostasis drive neuronal pathology in diabetes. Cell Calcium 1: 112-122, 2008.
26. Juvonen, T., Lemaître, R.N., Rea, T.D., Sotodoshina, E., Empena, J.P. and Siscovick, D.S.: Diabetes, glucose level, and risk of sudden cardiac death. Eur Heart J 26: 2142-2147, 2005.
27. Yeung EH, Pankow JS, Torok BC, Powe NR, Saudek CD and Kao WH: Increased risk of type 2 diabetes from a family history of coronary heart disease and type 2 diabetes. Diabetes Care 30: 154-156, 2007.
28. Rubler S, Dlugash J, Yuceloglu YZ, Kumral T, Branwood AW and Grishman A: New type of cardiomyopathy associated with diabetes mellitus and sudden cardiac death: What are the data? Cardiol J 17: 117-129, 2010.
29. Aharinejad S, Andrukhova O, Lucas T, Zuckermann A, Wieiselther G, Wolner E and Grimm M: Programmed cell death and heart failure in diabetic cardiomyopathy. Cardiovasc Pathol 17: 117-129, 2010.
33. Boudina S and Abel ED: Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 11: 31-39, 2010.
34. Kanai M, Otsuka Y, Otsuka K, Sato M, Nishimura T, Mori Y, Kawaguchi M, Hatano E, Kudoh Y, Matsumoto S, et al.: A phase 1 study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. Cancer Chemother Pharmacol 71: 1521-1530, 2013.
35. Sasaki H, Sunagawa Y, Takashashi K, Imaizumi A, Fukuda H, Hashimoto T, Wada H, Katsanasa Y, Kakeya H, Fujita M, et al.: Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull 34: 660-665, 2011.
36. van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Gonzalez-Quesada C, Cavaler M, Biernacka A, Kong P, Fric J, Zelante T, Wong Y, Mertes A, Yu HB and Unger T: Calcium channel blockade limits cardiac remodeling and improves cardiac function in myocardial infarction-induced heart failure in rats. J Cardiovasc Pharmacol 37: 64-77, 2001.
37. Kelly DJ and Connolly KA: High glucose induces Smad activation in the hindbrain and spinal cord of the rat. J Comp Neurol 375: 1379-1386, 2012.
38. Li M, Bao Y, Wu J, and Huang L: CaN-NFAT3 signal pathway: A crucial hinge relays Ca2+ signal with cardiomyocyte hypertrophy. Zhonghua Nei Ke Za Zhi 43: 19-21, 2004 (in Chinese).
39. Wilkins BJ, Dai YS, Bueno F, Parsons S, Xu J, Plank DM, Haq S, Choukroun G, Lim H, Tymitz KM, del Monte F, Bao 26: 405-408, 2001 (in Chinese).
40. Somvanshi RK, Zou S, Qiu X and Kumar U: Somatostatin receptor-2 negatively regulates β-adrenergic receptor mediated Ca2+ dependent signaling pathways in H9c2 cells. Biochim Biophys Acta 1843: 735-745, 2014.
41. Hsu SC, Chang YT and Chen SC: Early growth response 1 is an sglr-1-dependent calcium Cav3.2 T-type calcium channels during cardiac hypertrophy. Cardiovasc Res 100: 222-230, 2013.
42. Lee SD, Kuo WW, Lin DY, Chen TH, Kuo WH, Hsu HH, Chen JZ, Liu JY, Yeh YL and Huang CY: Role of calcineurin in Porphyromonas gingivalis-induced myocardial cell hypertrophy and apoptosis. Biochem Biophys Acta 1780: 251-260, 2006.
43. Strack S, Wadzinski BE and Ebner FF: Localization of the calcium/calmodulin-dependent protein phosphatase, calcineurin, in the hindbrain and spinal cord of the rat. J Comp Neurol 375: 66-76, 1996.
44. Smedler E and Uhlen P: Frequency decoding of calcium oscillations. Biochim Biophys Acta 1840: 964-969, 2014.
45. Fric J, Zelante T, Wong CY, Mertes A, Yu HB and Ricciardi-Castagnoli P: NFAT control of innate immunity. Blood 120: 1380-1389, 2012.
46. Somvanshi RK, Meurer S, Zeyer M and Giese T: Calcineurin inhibitors and NFAT-regulated gene expression. Clin Chim Acta 413: 1379-1386, 2012.
47. Maguire O, Tornatore KM, O’loughlin KL, Venuto RC and Minderman H: Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimus. Cytometry A 83: 1060-1104, 2013.
48. Hess P: Calcium channels in vertebrate cells. Annu Rev Neurosci 13: 337-356, 1990.
49. Rampe DG and Triggles DJ: New synthetic ligands for L-type voltage-gated calcium channels. Prog Drug Res 40: 191-238, 1993.
50. Katz AM: Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol 12: 522-530, 1988.
51. Triggles DJ: Calcium-channel antagonists: Mechanisms of action, vascular selectivities, and clinical relevance. Cleve Clin J Med 59: 617-627, 1992.
52. Maguire O, O’loughlin KL, Venuto RC and Minderman H: Nuclear accumulation of the transcription factor NFAT in cardiac myocytes: an early signal inducing Cav3.2 T-type calcium channels during cardiac remodeling. Mol Cell Biochem 1843: 735-745, 2005.
53. Fric J, Zelante T, Wong CY, Mertes A, Yu HB and Ricciardi-Castagnoli P: NFAT control of innate immunity. Blood 120: 1380-1389, 2012.